Enveda

Research on the record

• 2026-10-27Across its runs, Enveda's document reviewer raised all 11 issues human reviewers found in 1,061 pages of batch records, and 7 they had notLevel 3 · Checked against existing evidence
• 2026-08-18Enveda reports ENV-308, a pill built to mimic an exercise hormone, was well tolerated in 88 healthy volunteersLevel 5 · Used in practice
• 2026-07-24Enveda reports an oral eczema pill cut skin scores 85% by day 42 in nine patientsLevel 5 · Used in practice

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-10-27Anthropic buys a one-person drug company and starts running drug programmes of its ownOrganizations
• 2026-09-23Enveda raises $311M for medicines its AI finds in natural compoundsCapital

People

The leadership the company's own team page lists, then the other people the AI4S.fyi record has named. Not the full team.

Funding rounds tracked

• 2026-09-23Series E · $311MconfirmedLed by Catalio Capital Management · With Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (Citadel), T. Rowe Price, Baillie Gifford, Digitalis Ventures, Alderline Group, Premji Invest, FPV, True Ventures, Kinnevik, Dimension, Lifeforce Capital, Lux CapitalStated use: move ENV-294 and ENV-308 into later-stage trials
• 2025-09-04Series D · $150MconfirmedLed by Premji Invest · With Baillie Gifford, Kinnevik, Lingotto, FPV, Dimension, Lux Capital, Peakline Partners, Socium Ventures, Level Ventures, Henry Kravis, IA VenturesStated use: advance ENV-294 and the pipeline
• 2025-02Series C extension · Sanofi investment, amount not stated; brings Series C to $150MconfirmedWith SanofiStated use: expand clinical pipeline and AI discovery
• 2024-11-21Series C · $130MconfirmedLed by Kinnevik, FPV · With Baillie Gifford, Premji Invest, Lingotto, Lux Capital, Dimension, Henry R. Kravis, True Ventures, Cresset Partners, The Nature ConservancyStated use: reach clinical readouts in 2025-26 across programs
• 2024-06Series B extension · $55MreportedWith Premji Invest, Lingotto, Microsoft, The Nature ConservancyStated use: start clinical trials in late 2024 and early 2025
• 2023-04Series B1 · $51MreportedWith Henry KravisStated use: advance multiple programs toward the clinic
• 2022-12-21Series B · $68MconfirmedLed by Dimension · With FPV, Jazz Venture Partners, True Ventures, Lux Capital, Two Sigma Ventures, Wireframe Ventures, Level Ventures, Amino Collective, Allen & Co, Possible Ventures, Hummingbird VenturesStated use: advance lead compounds to clinical candidates
• 2021-06-22Series A · $51MconfirmedLed by Lux Capital · With Two Sigma Ventures, Hummingbird Ventures, Catalio Capital Management, Lifeforce Capital, Matthew De Silva (Notable Labs), True Ventures, Wireframe Ventures, Village Global, Chris Gibson (Recursion)Stated use: advance its platform to discover and develop drug candidates from its chemical map of the natural world
• 2020-12-16Seed · $4.9MconfirmedLed by True Ventures · With Wireframe Ventures, Village Global, Chris Gibson (Recursion)Stated use: grow its medicinal plant dataset, improve its technology and algorithms, and take its liver-fibrosis lead asset through preclinical development

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
• 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
• 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
• 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
• 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
• 2026-10-14Iambic TherapeuticsIPO · $150MDesigns small-molecule cancer drugs with AI structure-prediction models (NeuralPLexer) linked to an automated chemistry and biology lab.

All 37 in this field →